• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)].《免疫功能低下人群难治性/耐药性巨细胞病毒感染诊断与治疗策略中国专家共识（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):402-409. doi: 10.3760/cma.j.cn121090-20250112-00024.
2
The importance of drug exposure in the development of cytomegalovirus resistance.药物暴露在巨细胞病毒耐药性发展中的重要性。
Int J Antimicrob Agents. 2025 Sep;66(3):107537. doi: 10.1016/j.ijantimicag.2025.107537. Epub 2025 May 13.
3
Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study.德国实体器官和造血干细胞移植后巨细胞病毒血症及疾病的患者数量和治疗模式：德尔菲共识研究结果
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03210-x.
4
WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.撤回：实体器官移植中使用抗病毒药物进行巨细胞病毒预防。
Cochrane Database Syst Rev. 2007 Jul 18;1998(4):CD001320. doi: 10.1002/14651858.CD001320.pub2.
5
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.对巨细胞病毒血症进行抢先治疗以预防实体器官移植受者的巨细胞病毒疾病。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD005133. doi: 10.1002/14651858.CD005133.pub3.
6
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明：2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
7
Emerging concepts of CMV in transplantation.移植领域中巨细胞病毒的新观念。
Intern Med J. 2025 Jan;55(1):12-19. doi: 10.1111/imj.16587. Epub 2024 Dec 2.
8
Inter-laboratory variability in cytomegalovirus DNA quantification: implications for standardization and clinical monitoring.巨细胞病毒DNA定量分析中的实验室间变异性：对标准化和临床监测的影响
J Clin Microbiol. 2025 Jul 9;63(7):e0191124. doi: 10.1128/jcm.01911-24. Epub 2025 Jun 5.
9
Long-term prognosis following cytomegalovirus respiratory infection in immunocompromised and immunocompetent patients: a retrospective single-centre study.免疫功能低下和免疫功能正常患者巨细胞病毒呼吸道感染后的长期预后：一项回顾性单中心研究
BMC Infect Dis. 2025 May 26;25(1):756. doi: 10.1186/s12879-025-11162-4.
10
Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial.基于治疗药物监测的缬更昔洛韦对巨细胞病毒感染进行抢先治疗的优化：一项II期单中心单臂试验方案
JMIR Res Protoc. 2025 Jun 24;14:e72549. doi: 10.2196/72549.

本文引用的文献

1
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.移植相关病毒感染论坛：用于临床试验的移植患者中巨细胞病毒（CMV）感染和疾病（包括耐药和难治性 CMV）的共识定义：2024 年更新。
Clin Infect Dis. 2024 Sep 26;79(3):787-794. doi: 10.1093/cid/ciae321.
2
Case Report: Cytomegalovirus-specific T-lymphocyte infusion for resistant cytomegalovirus retinitis.病例报告：巨细胞病毒特异性T淋巴细胞输注治疗耐药性巨细胞病毒性视网膜炎
Front Ophthalmol (Lausanne). 2023 Jul 3;3:1131674. doi: 10.3389/fopht.2023.1131674. eCollection 2023.
3
[Current status and progresses of cytomegalovirus infection management after hematopoietic stem cell transplantation in China].[中国造血干细胞移植后巨细胞病毒感染管理的现状与进展]
Zhonghua Nei Ke Za Zhi. 2024 Feb 1;63(2):217-224. doi: 10.3760/cma.j.cn112138-20230811-00045.
4
Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation.异基因造血干细胞移植后难治性巨细胞病毒血症和疾病的细胞巨化病毒特异性细胞毒性 T 淋巴细胞过继治疗。
Br J Haematol. 2024 Apr;204(4):1393-1401. doi: 10.1111/bjh.19282. Epub 2024 Jan 2.
5
Development and validation of a next-generation sequencing assay with open-access analysis software for detecting resistance-associated mutations in CMV.开发并验证了一种使用开放获取分析软件的下一代测序检测方法，用于检测 CMV 中的耐药相关突变。
J Clin Microbiol. 2023 Dec 19;61(12):e0082923. doi: 10.1128/jcm.00829-23. Epub 2023 Nov 21.
6
Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.在 AURORA 试验中造血细胞移植后首次巨细胞病毒感染的治疗：一项比较马拉韦罗与缬更昔洛韦的多中心、双盲、随机、3 期临床试验。
Clin Infect Dis. 2024 Mar 20;78(3):562-572. doi: 10.1093/cid/ciad709.
7
Genetic Variants Associated with Drug Resistance of Cytomegalovirus in Hematopoietic Cell Transplantation Recipients.与造血细胞移植受者巨细胞病毒耐药性相关的遗传变异。
Viruses. 2023 May 30;15(6):1286. doi: 10.3390/v15061286.
8
Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.移植受者巨细胞病毒感染的口服抗病毒药物治疗。
Clin Microbiol Infect. 2023 Sep;29(9):1144-1149. doi: 10.1016/j.cmi.2023.03.020. Epub 2023 Mar 23.
9
[The Chinese consensus on the management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation patients (2022)].《2022年异基因造血干细胞移植患者巨细胞病毒感染管理的中国专家共识》
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):617-623. doi: 10.3760/cma.j.issn.0253-2727.2022.08.001.
10
New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.实体器官移植患者巨细胞病毒管理的新见解：耐药/难治性疾病的预防、治疗与管理
Infect Dis Ther. 2023 Feb;12(2):333-342. doi: 10.1007/s40121-022-00746-1. Epub 2022 Dec 30.

《免疫功能低下人群难治性/耐药性巨细胞病毒感染诊断与治疗策略中国专家共识（2025年版）》

[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)].

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):402-409. doi: 10.3760/cma.j.cn121090-20250112-00024.

DOI:10.3760/cma.j.cn121090-20250112-00024
PMID:40623898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12268285/
Abstract

The number of immunocompromised individuals in China is rapidly increasing, and the incidence of cytomegalovirus (CMV) infection in this population is significantly higher than in the general population, severely affecting their quality of life and prognosis. Currently, a standardized diagnostic and treatment system for refractory/resistant CMV infections in immunocompromised populations is lacking. Based on domestic and international data on the epidemiology, evidence-based medicine, and clinical research regarding refractory/resistant CMV infections, this consensus formulates recommendations for the diagnosis, treatment, and management of these infections.

摘要

中国免疫功能低下人群的数量正在迅速增加，该人群中巨细胞病毒（CMV）感染的发生率显著高于普通人群，严重影响他们的生活质量和预后。目前，免疫功能低下人群难治性/耐药性CMV感染缺乏标准化的诊断和治疗体系。基于国内外关于难治性/耐药性CMV感染的流行病学、循证医学及临床研究数据，本共识制定了这些感染的诊断、治疗及管理建议。